Nueva generación de insulinas: glargina U300: Resumen de evidencia clínica

Musso, Carla; Capurro, Lina; Mingote, Evelin; Forti, Luján; Guaita, María Silvina.
Medicina (B.Aires) ; 79(4): 241-250, ago. 2019. ilus, graf, tab
Artículo en Español | LILACS | ID: biblio-1040516

Documentos relacionados

  1. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
  2. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
  3. [New generation of insulins: glargine U300. Summary of clinical evidence].
  4. Unmet needs in children with diabetes: the role of basal insulin.
  5. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
  6. Glargine insulin loaded lipid nanoparticles: Oral delivery of liquid and solid oral dosage forms.
  7. Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.
  8. Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non-inferiority randomized trial.
  9. Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.
  10. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.